Ironwood Pharmaceuticals, Inc. IRWD
4.13
(0.06)
(1.43%)
as of 25 Sep
- Market cap
- $692.4M
- P/E
- 5.2×
Follow IRWD
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (55.26%) | (37.07%) | (8.53%) | (9.92%) |
+8 more TTM periods Free account |
|
| 41.35% | 26.83% | 6.42% | 7.27% | ||
ROIC |
101.61% | 84.97% | 57.33% | 42.79% | |
Return on Tangible Assets |
76.73% | 103.05% | 67.91% | 81.55% | |
Average Days of Receivables |
105.69 | 106.86 | 57.61 | 129.61 | |
Free Cash Flow per Share |
1.13 | 0.69 | 0.78 | 0.42 | |
Free Cash Flow |
185.56 | 112.21 | 127.01 | 67.65 | |
Capital Expenditures |
— | — | (0.03) | (0.03) | |
Piotroski F-Score |
6.00 | 6.00 | 5.00 | 6.00 | |
| Other line items | |||||
Cash ROIC |
61.38% | 19.08% | 23.60% | 14.69% | |
Accounts Receivable Turnover |
3.91 | 4.97 | 4.60 | 3.45 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.37) | (0.40) | (0.66) | (0.69) | |
Research and Development Expense of Revenue |
22.78% | 24.80% | 32.12% | 29.11% | |
Selling, General and Administrative Expense of Revenue |
16.58% | 19.37% | 27.78% | 28.48% | |
Share Based Compensation of Revenue |
3.68% | 4.32% | 5.82% | 5.31% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.43 | 1.10 | 5.29 | 2.37 | |
Depreciation/Fixed assets |
0.63 | 0.58 | 0.55 | 0.52 | |
Capex/Depreciation |
0.00 | 0.00 | (0.02) | (0.02) | |
Revenue per Share |
2.37 | 2.21 | 1.83 | 2.09 | |
Operating CF per Share |
1.13 | 0.69 | 0.79 | 0.42 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
33.36% | 28.26% | 8.11% | 8.42% |
Columns are period end dates